Marinomed Biotech AG (WBO:MARI) EV-to-EBIT : -8.76 (As of May. 01, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Marinomed Biotech AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Marinomed Biotech AG's Enterprise Value is €45.40 Mil. Marinomed Biotech AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.18 Mil. Therefore, Marinomed Biotech AG's EV-to-EBIT for today is -8.76.

The historical rank and industry rank for Marinomed Biotech AG's EV-to-EBIT or its related term are showing as below:

WBO:MARI' s EV-to-EBIT Range Over the Past 10 Years
Min: -39.65 Med: -24.29 Max: -7.9
Current: -8.76

During the past 9 years, the highest EV-to-EBIT of Marinomed Biotech AG was -7.90. The lowest was -39.65. And the median was -24.29.

WBO:MARI's EV-to-EBIT is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 8.18 vs WBO:MARI: -8.76

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Marinomed Biotech AG's Enterprise Value for the quarter that ended in Dec. 2023 was €63.70 Mil. Marinomed Biotech AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.18 Mil. Marinomed Biotech AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -8.14%.

Marinomed Biotech AG EV-to-EBIT Historical Data

The historical data trend for Marinomed Biotech AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinomed Biotech AG EV-to-EBIT Chart

Marinomed Biotech AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-21.32

-33.79

-33.51

-25.60

-14.81

Marinomed Biotech AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-25.60	-15.70	-16.92	-17.14	-14.81

Competitive Comparison of Marinomed Biotech AG's EV-to-EBIT

For the Biotechnology subindustry, Marinomed Biotech AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marinomed Biotech AG's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Marinomed Biotech AG's EV-to-EBIT falls into.

Marinomed Biotech AG EV-to-EBIT Calculation

Marinomed Biotech AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	45.398	/	-5.184
	=	-8.76

Marinomed Biotech AG's current Enterprise Value is €45.40 Mil.
Marinomed Biotech AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.18 Mil.

Marinomed Biotech AG (WBO:MARI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Marinomed Biotech AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-5.184	/	63.703836
	=	-8.14 %

Marinomed Biotech AG's Enterprise Value for the quarter that ended in Dec. 2023 was €63.70 Mil.
Marinomed Biotech AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.18 Mil.

Marinomed Biotech AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Marinomed Biotech AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinomed Biotech AG (WBO:MARI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinomed Biotech AG (WBO:MARI) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

93Z:Germany

Address

Hovengasse 25, Korneuburg, AUT, 2100

Website

https://www.marinomed.com

Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generates from the virology segment.

Marinomed Biotech AG (WBO:MARI) Headlines

No Headlines